Eikon Therapeutics (EIKN) vs Ocugen (OCGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ocugen is the larger company by market cap ($260.6 million vs $256.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EIKN | OCGN |
|---|---|---|
| Share price | $4.74 | $0.7679 |
| Market cap | $256.84M | $260.55M |
| 1-day change | -0.42% | +4.79% |
| YTD return | — | -43.12% |
| 1-year return | — | -33.80% |
| 5-year return | — | -88.09% |
| EPS (TTM) | $-7.86 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.41M |
| Revenue growth (YoY) | — | +8.83% |
| Net income (latest FY) | — | $-67.85M |
| Operating margin | — | -1425.70% |
| Net margin | — | -1537.41% |
| 52-week high | $17.40 | $2.73 |
| 52-week low | $4.72 | $0.691 |
| Distance from 52-week high | -72.76% | -71.82% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +406.33% | +1484.84% |
| Average volume | 560.40K | 7.34M |
| Shares outstanding | 54.19M | 339.31M |
| Employees | 384 | 116 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
EIKN vs OCGN FAQ
Which is bigger, Eikon Therapeutics or Ocugen?
Ocugen (OCGN) is larger, with a market capitalization of $260.55M compared with $256.84M for Eikon Therapeutics (EIKN).
Are Eikon Therapeutics and Ocugen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.